Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 857

1.

Abnormal accumulation of p53 predicts radioresistance leading to poor survival in patients with endometrial carcinoma.

Akiyama A, Minaguchi T, Fujieda K, Hosokawa Y, Nishida K, Shikama A, Tasaka N, Sakurai M, Ochi H, Satoh T.

Oncol Lett. 2019 Dec;18(6):5952-5958. doi: 10.3892/ol.2019.10940. Epub 2019 Sep 30.

2.

A case of overlapping adult-onset linear scleroderma and Parry-Romberg syndrome presenting with widespread ipsilateral neurogenic involvement.

Yamasaki R, Yonekawa T, Inamizu S, Shinoda K, Ochi H, Matsushita T, Isobe N, Tsuji G, Sadashima S, Kuma Y, Oda Y, Iwaki T, Furue M, Kira JI.

Neuropathology. 2019 Nov 27. doi: 10.1111/neup.12614. [Epub ahead of print]

PMID:
31775183
3.

Quantitative susceptibility mapping of prostate with separate calculations for water and fat regions for reducing shading artifacts.

Sato R, Shirai T, Soutome Y, Bito Y, Ochi H.

Magn Reson Imaging. 2019 Nov 9;66:22-29. doi: 10.1016/j.mri.2019.11.006. [Epub ahead of print]

PMID:
31715250
4.

Safety and efficacy of lenvatinib in elderly patients with unresectable hepatocellular carcinoma: a multicenter analysis with propensity score matching.

Tada T, Kumada T, Hiraoka A, Michitaka K, Atsukawa M, Hirooka M, Tsuji K, Ishikawa T, Takaguchi K, Kariyama K, Itobayashi E, Tajiri K, Shimada N, Shibata H, Ochi H, Toyoda H, Nouso K, Tsutsui A, Nagano T, Itokawa N, Hayama K, Imai M, Joko K, Koizumi Y, Hiasa Y; Real-life Practice Experts for HCC (RELPEC) Study Group and the HCC 48 Group (Hepatocellular carcinoma experts from 48 clinics in Japan).

Hepatol Res. 2019 Oct 29. doi: 10.1111/hepr.13427. [Epub ahead of print]

PMID:
31660700
5.

Coronary artery stenosis-related perfusion ratio using dynamic computed tomography myocardial perfusion imaging: a pilot for identification of hemodynamically significant coronary artery disease.

Kuwahara N, Tanabe Y, Kido T, Kurata A, Uetani T, Ochi H, Kawaguchi N, Kido T, Ikeda S, Yamaguchi O, Asano M, Mochizuki T.

Cardiovasc Interv Ther. 2019 Oct 19. doi: 10.1007/s12928-019-00627-4. [Epub ahead of print]

PMID:
31630340
6.

The long noncoding RNA Crnde regulates osteoblast proliferation through the Wnt/β-catenin signaling pathway in mice.

Mulati M, Kobayashi Y, Takahashi A, Numata H, Saito M, Hiraoka Y, Ochi H, Sato S, Ezura Y, Yuasa M, Hirai T, Yoshii T, Okawa A, Inose H.

Bone. 2020 Jan;130:115076. doi: 10.1016/j.bone.2019.115076. Epub 2019 Oct 14.

PMID:
31622775
7.

Development and validation of a real-time multiplex PCR assay for the detection of dermatophytes and Fusarium spp.

Koo SH, Teoh YL, Koh WL, Ochi H, Tan SK, Sim DMF, Jiang B, Tan AL, Tan TY, Lim SPR.

J Med Microbiol. 2019 Nov;68(11):1641-1648. doi: 10.1099/jmm.0.001082.

PMID:
31526456
8.
9.

Comparative analysis demonstrates cell type-specific conservation of SOX9 targets between mouse and chicken.

Yamashita S, Kataoka K, Yamamoto H, Kato T, Hara S, Yamaguchi K, Renard-Guillet C, Katou Y, Shirahige K, Ochi H, Ogino H, Uchida T, Inui M, Takada S, Shigenobu S, Asahara H.

Sci Rep. 2019 Aug 29;9(1):12560. doi: 10.1038/s41598-019-48979-4.

10.

Early Relative Change in Hepatic Function with Lenvatinib for Unresectable Hepatocellular Carcinoma.

Hiraoka A, Kumada T, Atsukawa M, Hirooka M, Tsuji K, Ishikawa T, Takaguchi K, Kariyama K, Itobayashi E, Tajiri K, Shimada N, Shibata H, Ochi H, Tada T, Toyoda H, Nouso K, Tsutsui A, Nagano T, Itokawa N, Hayama K, Imai M, Joko K, Koizumi Y, Hiasa Y, Michitaka K; On behalf of the Real-Life Practice Experts for HCC (RELPEC) Study Group and HCC 48 Group (hepatocellular carcinoma experts from 48 clinics in Japan).

Oncology. 2019;97(6):334-340. doi: 10.1159/000502095. Epub 2019 Aug 29.

PMID:
31466068
11.

Role of severe thrombocytopenia in preventing platelet count recovery in thrombocytopenic patients with chronic liver disease.

Hirooka M, Ochi H, Hiraoka A, Koizumi Y, Tanaka T, Sunago K, Yukimoto A, Imai Y, Watanabe T, Yoshida O, Abe M, Joko K, Michitaka K, Hiasa Y.

J Gastroenterol Hepatol. 2019 Jul 18. doi: 10.1111/jgh.14786. [Epub ahead of print]

PMID:
31318996
12.

Important Clinical Factors in Sequential Therapy Including Lenvatinib against Unresectable Hepatocellular Carcinoma.

Hiraoka A, Kumada T, Atsukawa M, Hirooka M, Tsuji K, Ishikawa T, Takaguchi K, Kariyama K, Itobayashi E, Tajiri K, Shimada N, Shibata H, Ochi H, Tada T, Toyoda H, Nouso K, Tsutsui A, Nagano T, Itokawa N, Hayama K, Imai M, Joko K, Tanaka H, Tamai T, Koizumi Y, Hiasa Y, Michitaka K, Kudo M; Real-life Practice Experts for HCC (RELPEC) Study Group; HCC 48 Group (hepatocellular carcinoma experts from 48 clinics in Japan).

Oncology. 2019;97(5):277-285. doi: 10.1159/000501281. Epub 2019 Jul 15.

PMID:
31307035
13.

Autograft-prosthesis composite use for a Vancouver type B1 periprosthetic femur fracture with pelvic acetabular component migration after bipolar hemiarthroplasty: A case report.

Ochi H, Baba T, Tanabe H, Ozaki Y, Watari T, Homma Y, Matsumoto M, Kaneko K.

Trauma Case Rep. 2019 Jun 21;22:100213. doi: 10.1016/j.tcr.2019.100213. eCollection 2019 Aug.

14.

The L-type amino acid transporter LAT1 inhibits osteoclastogenesis and maintains bone homeostasis through the mTORC1 pathway.

Ozaki K, Yamada T, Horie T, Ishizaki A, Hiraiwa M, Iezaki T, Park G, Fukasawa K, Kamada H, Tokumura K, Motono M, Kaneda K, Ogawa K, Ochi H, Sato S, Kobayashi Y, Shi YB, Taylor PM, Hinoi E.

Sci Signal. 2019 Jul 9;12(589). pii: eaaw3921. doi: 10.1126/scisignal.aaw3921.

PMID:
31289211
15.

Environmental Oxygen Exposure Allows for the Evolution of Interdigital Cell Death in Limb Patterning.

Cordeiro IR, Kabashima K, Ochi H, Munakata K, Nishimori C, Laslo M, Hanken J, Tanaka M.

Dev Cell. 2019 Jul 22;50(2):155-166.e4. doi: 10.1016/j.devcel.2019.05.025. Epub 2019 Jun 13.

PMID:
31204171
16.

Lenvatinib-induced thyroid abnormalities in unresectable hepatocellular carcinoma.

Koizumi Y, Hirooka M, Hiraoka A, Ochi H, Tanaka T, Yukimoto A, Imai Y, Watanabe T, Yoshida O, Miyake T, Matsuura B, Michitaka K, Joko K, Abe M, Hiasa Y.

Endocr J. 2019 Sep 28;66(9):787-792. doi: 10.1507/endocrj.EJ19-0140. Epub 2019 May 30.

17.

Prebiotic effect of two grams of lactulose in healthy Japanese women: a randomised, double-blind, placebo-controlled crossover trial.

Sakai Y, Seki N, Hamano K, Ochi H, Abe F, Masuda K, Iino H.

Benef Microbes. 2019 May 27:1-12. doi: 10.3920/BM2018.0174. [Epub ahead of print]

PMID:
31131617
18.

Prognostic factor of lenvatinib for unresectable hepatocellular carcinoma in real-world conditions-Multicenter analysis.

Hiraoka A, Kumada T, Atsukawa M, Hirooka M, Tsuji K, Ishikawa T, Takaguchi K, Kariyama K, Itobayashi E, Tajiri K, Shimada N, Shibata H, Ochi H, Tada T, Toyoda H, Nouso K, Tsutsui A, Nagano T, Itokawa N, Hayama K, Imai M, Joko K, Koizumi Y, Hiasa Y, Michitaka K, Kudo M; Real-life Practice Experts for HCC (RELPEC) Study Group, HCC 48 Group (hepatocellular carcinoma experts from 48 clinics in Japan).

Cancer Med. 2019 Jul;8(8):3719-3728. doi: 10.1002/cam4.2241. Epub 2019 May 24.

19.

A study of the prebiotic effect of lactulose at low dosages in healthy Japanese women.

Sakai Y, Seki N, Hamano H, Ochi H, Abe F, Shimizu F, Masuda K, Iino H.

Biosci Microbiota Food Health. 2019;38(2):69-72. doi: 10.12938/bmfh.18-013. Epub 2018 Dec 29.

20.

Predictors of favorable survival after secondary cytoreductive surgery for recurrent endometrial cancer.

Shikama A, Minaguchi T, Takao W, Hosokawa Y, Nishida K, Tasaka N, Akiyama A, Sakurai M, Ochi H, Satoh T.

Int J Clin Oncol. 2019 Oct;24(10):1256-1263. doi: 10.1007/s10147-019-01469-z. Epub 2019 May 16.

PMID:
31098693
21.

Real-world efficacy of elbasvir and grazoprevir for hepatitis C virus (genotype 1): A nationwide, multicenter study by the Japanese Red Cross Hospital Liver Study Group.

Mashiba T, Joko K, Kurosaki M, Ochi H, Hasebe C, Akahane T, Sohda T, Tsuji K, Mitsuda A, Kimura H, Narita R, Ogawa C, Furuta K, Shigeno M, Okushin H, Ito H, Kusakabe A, Satou T, Kawanami C, Nakata R, Kobashi H, Tamada T, Ide Y, Yagisawa H, Morita A, Matsushita T, Okada K, Izumi N.

Hepatol Res. 2019 Oct;49(10):1114-1120. doi: 10.1111/hepr.13362. Epub 2019 Jun 14.

PMID:
31077527
22.

Validation of Modified ALBI Grade for More Detailed Assessment of Hepatic Function in Hepatocellular Carcinoma Patients: A Multicenter Analysis.

Hiraoka A, Kumada T, Tsuji K, Takaguchi K, Itobayashi E, Kariyama K, Ochi H, Tajiri K, Hirooka M, Shimada N, Ishikawa T, Tachi Y, Tada T, Toyoda H, Nouso K, Joko K, Hiasa Y, Michitaka K, Kudo M.

Liver Cancer. 2019 Mar;8(2):121-129. doi: 10.1159/000488778. Epub 2018 Jun 11.

23.

Combination of Resection and Ablative Treatment for Hepatocellular Carcinoma: Usefulness of Complementary Radiofrequency Ablation.

Hiraoka A, Hirooka M, Ochi H, Koizumi Y, Izumoto H, Ueki H, Tsuruta M, Ono A, Yoshino T, Aibiki T, Okudaira T, Yamago H, Suga Y, Iwasaki R, Mori K, Miyata H, Kishida M, Tsubouchi E, Abe M, Matsuura B, Ninomiya T, Joko K, Kawasaki H, Hiasa Y, Michitaka K.

Oncology. 2019;96(5):242-251. doi: 10.1159/000496225. Epub 2019 Mar 20.

PMID:
30893698
24.

Pep-MS assay: Protease hydrolysis assay system using photo-cleavable peptide array and mass spectrometer.

Kurimoto M, Shimizu K, Ochi H, Abe F, Honda H.

J Biosci Bioeng. 2019 Aug;128(2):156-161. doi: 10.1016/j.jbiosc.2019.02.005. Epub 2019 Mar 9.

PMID:
30862433
25.

Ser96Ala genetic variant of the human histidine-rich calcium-binding protein is a genetic predictor of recurrence after catheter ablation in patients with paroxysmal atrial fibrillation.

Amioka M, Nakano Y, Ochi H, Onohara Y, Sairaku A, Tokuyama T, Motoda C, Matsumura H, Tomomori S, Hironobe N, Okubo Y, Okamura S, Chayama K, Kihara Y.

PLoS One. 2019 Mar 6;14(3):e0213208. doi: 10.1371/journal.pone.0213208. eCollection 2019.

26.

Pericytes as a Source of Osteogenic Cells in Bone Fracture Healing.

Supakul S, Yao K, Ochi H, Shimada T, Hashimoto K, Sunamura S, Mabuchi Y, Tanaka M, Akazawa C, Nakamura T, Okawa A, Takeda S, Sato S.

Int J Mol Sci. 2019 Mar 2;20(5). pii: E1079. doi: 10.3390/ijms20051079.

27.

Clinical and MRI Characteristics of Uterine Cervical Adenocarcinoma: Its Variants and Mimics.

Saida T, Sakata A, Tanaka YO, Ochi H, Ishiguro T, Sakai M, Takahashi H, Satoh T, Minami M.

Korean J Radiol. 2019 Mar;20(3):364-377. doi: 10.3348/kjr.2018.0458. Review.

28.

[Sports and Physical Exercise in Multiple Sclerosis].

Ochi H.

Brain Nerve. 2019 Feb;71(2):143-152. doi: 10.11477/mf.1416201233. Review. Japanese.

PMID:
30718443
29.

Correction: Reduction of hepatitis B surface antigen in sequential versus add-on pegylated interferon to nucleoside/nucleotide analogue therapy in HBe-antigen-negative chronic hepatitis B patients: a pilot study.

Tatsukawa Y, Tsuge M, Kawakami Y, Hiyama Y, Murakami E, Kurihara M, Nomura M, Tsushima K, Uchida T, Nakahara T, Miki D, Kawaoka T, Abe-Chayama H, Imamura M, Aikata H, Ochi H, Hayes CN, Kawakami H, Chayama K.

Antivir Ther. 2019;23(8):709. doi: 10.3851/IMP3289. No abstract available.

PMID:
30632982
30.

The Clinical Potential of Impella 5.0 Support in the Treatment of Recurrent Fulminant Viral Myocarditis with Profound Cardiogenic Shock.

Ogawa S, Suzuki M, Ochi H, Saji M, Mahara K, Takamisawa I, Nishigawa K, Furuichi Y, Takanashi S, Isobe M.

Intern Med. 2019 May 15;58(10):1459-1462. doi: 10.2169/internalmedicine.1866-18. Epub 2019 Jan 10.

31.

Arid3a regulates nephric tubule regeneration via evolutionarily conserved regeneration signal-response enhancers.

Suzuki N, Hirano K, Ogino H, Ochi H.

Elife. 2019 Jan 8;8. pii: e43186. doi: 10.7554/eLife.43186.

32.

Clinical features of lenvatinib for unresectable hepatocellular carcinoma in real-world conditions: Multicenter analysis.

Hiraoka A, Kumada T, Kariyama K, Takaguchi K, Atsukawa M, Itobayashi E, Tsuji K, Tajiri K, Hirooka M, Shimada N, Shibata H, Ishikawa T, Ochi H, Tada T, Toyoda H, Nouso K, Tsutsui A, Itokawa N, Imai M, Joko K, Hiasa Y, Michitaka K; Real-life Practice Experts for HCC (RELPEC) Study Group, HCC 48 Group (hepatocellular carcinoma experts from 48 clinics in Japan).

Cancer Med. 2019 Jan;8(1):137-146. doi: 10.1002/cam4.1909. Epub 2018 Dec 21.

33.

Impact of albumin-bilirubin grade on survival in patients with hepatocellular carcinoma who received sorafenib: An analysis using time-dependent receiver operating characteristic.

Tada T, Kumada T, Toyoda H, Tsuji K, Hiraoka A, Michitaka K, Deguchi A, Ishikawa T, Imai M, Ochi H, Joko K, Shimada N, Tajiri K, Hirooka M, Koizumi Y, Hiasa Y, Tanaka J.

J Gastroenterol Hepatol. 2019 Jun;34(6):1066-1073. doi: 10.1111/jgh.14564. Epub 2019 Feb 27.

PMID:
30549320
34.

Posterior versus direct anterior approach in total hip arthroplasty: difference in patient-reported outcomes measured with the Forgotten Joint Score-12.

Ozaki Y, Baba T, Homma Y, Ochi H, Watari T, Banno S, Matsumoto M, Kaneko K.

SICOT J. 2018;4:54. doi: 10.1051/sicotj/2018051. Epub 2016 Nov 27.

35.

Firm digital papulonodules in a young boy.

Ochi H, Puhaindran ME, Tan KW.

Int J Dermatol. 2019 Jan;58(1):91-92. doi: 10.1111/ijd.14276. Epub 2018 Nov 8. No abstract available.

PMID:
30411332
36.

The impact of interferon-free direct-acting antivirals on clinical outcome after curative treatment for hepatitis C virus-associated hepatocellular carcinoma: Comparison with interferon-based therapy.

Nagaoki Y, Imamura M, Nishida Y, Daijo K, Teraoka Y, Honda F, Nakamura Y, Morio K, Fujino H, Nakahara T, Kawaoka T, Tsuge M, Hiramatsu A, Kawakami Y, Miki D, Hiyama Y, Ochi H, Chayama K, Aikata H.

J Med Virol. 2019 Apr;91(4):650-658. doi: 10.1002/jmv.25352. Epub 2018 Nov 19.

PMID:
30381831
37.

Using ALBI score at the start of sorafenib treatment to predict regorafenib treatment candidates in patients with hepatocellular carcinoma.

Yukimoto A, Hirooka M, Hiraoka A, Michitaka K, Ochi H, Joko K, Imai Y, Watanabe T, Koizumi Y, Yoshida O, Abe M, Hiasa Y.

Jpn J Clin Oncol. 2019 Jan 1;49(1):42-47. doi: 10.1093/jjco/hyy153.

PMID:
30380075
38.

Loss of cyclin-dependent kinase 1 impairs bone formation, but does not affect the bone-anabolic effects of parathyroid hormone.

Takahashi A, Mulati M, Saito M, Numata H, Kobayashi Y, Ochi H, Sato S, Kaldis P, Okawa A, Inose H.

J Biol Chem. 2018 Dec 14;293(50):19387-19399. doi: 10.1074/jbc.RA118.004834. Epub 2018 Oct 26.

PMID:
30366983
39.

Destructive Thyroiditis Induced by Lenvatinib in Three Patients with Hepatocellular Carcinoma.

Hirooka M, Ochi H, Hiraoka A, Koizumi Y, Matsuura B, Joko K, Michitaka K, Abe M, Hiasa Y.

Intern Med. 2019 Mar 15;58(6):791-795. doi: 10.2169/internalmedicine.1874-18. Epub 2018 Oct 17.

40.

Novel prognostic predictor of brain atrophy in multiple sclerosis.

Ochi H.

J Neurol Neurosurg Psychiatry. 2019 Jan;90(1):3. doi: 10.1136/jnnp-2018-319376. Epub 2018 Oct 15. No abstract available.

PMID:
30322897
41.

Chromosome 4q25 Variant rs6817105 Bring Sinus Node Dysfunction and Left Atrial Enlargement.

Tomomori S, Nakano Y, Ochi H, Onohara Y, Sairaku A, Tokuyama T, Motoda C, Matsumura H, Amioka M, Hironobe N, Okubo Y, Okamura S, Kawazoe H, Nishiyama Y, Tahara H, Chayama K, Kihara Y.

Sci Rep. 2018 Oct 1;8(1):14565. doi: 10.1038/s41598-018-32453-8.

42.

Endoplasmic reticulum-mediated induction of interleukin-8 occurs by hepatitis B virus infection and contributes to suppression of interferon responsiveness in human hepatocytes.

Tsuge M, Hiraga N, Zhang Y, Yamashita M, Sato O, Oka N, Shiraishi K, Izaki Y, Makokha GN, Uchida T, Kurihara M, Nomura M, Tsushima K, Nakahara T, Murakami E, Abe-Chayama H, Kawaoka T, Miki D, Imamura M, Kawakami Y, Aikata H, Ochi H, Hayes CN, Fujita T, Chayama K.

Virology. 2018 Dec;525:48-61. doi: 10.1016/j.virol.2018.08.020. Epub 2018 Sep 18.

43.

Prospective cohort trial to confirm the efficacy of no-touch radio frequency ablation.

Hirooka M, Hiraoka A, Ochi H, Koizumi Y, Michitaka K, Joko K, Abe M, Hiasa Y.

J Gastroenterol Hepatol. 2019 Mar;34(3):567-574. doi: 10.1111/jgh.14476. Epub 2018 Oct 15.

PMID:
30225957
44.

Preoperative ultrasound to identify distribution of the lateral femoral cutaneous nerve in total hip arthroplasty using the direct anterior approach.

Ozaki Y, Baba T, Homma Y, Tanabe H, Ochi H, Bannno S, Watari T, Kaneko K.

SICOT J. 2018;4:42. doi: 10.1051/sicotj/2018037. Epub 2018 Sep 17.

45.
46.

Maintenance of low inflammation level by the ZFHX3 SNP rs2106261 minor allele contributes to reduced atrial fibrillation recurrence after pulmonary vein isolation.

Tomomori S, Nakano Y, Ochi H, Onohara Y, Sairaku A, Tokuyama T, Motoda C, Matsumura H, Amioka M, Hironobe N, Ookubo Y, Okamura S, Kawazoe H, Chayama K, Kihara Y.

PLoS One. 2018 Sep 4;13(9):e0203281. doi: 10.1371/journal.pone.0203281. eCollection 2018.

47.

Construction of a risk model for the development of metachronous squamous cell carcinoma after endoscopic resection of esopahageal squamous cell carcinoma.

Urabe Y, Kagemoto K, Nakamura K, Mizumoto T, Sanomura Y, Oka S, Ochi H, Tanaka S, Chayama K.

Esophagus. 2019 Apr;16(2):141-146. doi: 10.1007/s10388-018-0643-7. Epub 2018 Sep 1.

PMID:
30173282
48.

A rare case of acute pancreatitis caused by Candida Albicans.

Tange K, Yokota T, Sunago K, Aono M, Ochi H, Takechi S, Mashiba T, Hida AI, Oshiro Y, Joko K, Kumagi T, Hiasa Y.

Clin J Gastroenterol. 2019 Feb;12(1):82-87. doi: 10.1007/s12328-018-0896-7. Epub 2018 Aug 28.

PMID:
30155835
49.

Therapeutic potential of lenvatinib for unresectable hepatocellular carcinoma in clinical practice: Multicenter analysis.

Hiraoka A, Kumada T, Kariyama K, Takaguchi K, Itobayashi E, Shimada N, Tajiri K, Tsuji K, Ishikawa T, Ochi H, Hirooka M, Tsutsui A, Shibata H, Tada T, Toyoda H, Nouso K, Joko K, Hiasa Y, Michitaka K; Real-life Practice Experts for HCC (RELPEC) Study Group and the HCC 48 Group (hepatocellular carcinoma experts from 48 clinics in Japan).

Hepatol Res. 2019 Jan;49(1):111-117. doi: 10.1111/hepr.13243. Epub 2018 Oct 9.

PMID:
30144256
50.

Prognostic significance of PIK3CA mutation in stage IIB to IVA cervical cancers treated by concurrent chemoradiotherapy with weekly cisplatin.

Lachkar B, Minaguchi T, Akiyama A, Liu S, Zhang S, Xu C, Shikama A, Tasaka N, Sakurai M, Nakao S, Ochi H, Yoshikawa H, Satoh T.

Medicine (Baltimore). 2018 Aug;97(31):e11392. doi: 10.1097/MD.0000000000011392.

Supplemental Content

Support Center